- Assemblée générale 2024 de Roche
- Roche Generalversammlung 2024
- Roche Annual General Meeting 2024
- Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
- New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
- New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER)
- [Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19
- [Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 245.40 |
Average volume | -- |
---|---|
Shares outstanding | 809.25m |
Free float | 724.68m |
P/E (TTM) | 16.14 |
Market cap | 188.03bn CHF |
EPS (TTM) | 14.30 CHF |
Annual div (ADY) | 9.98 EUR |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 15 minutes, as of Jun 28 2019 07:11 BST.
More ▼